<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107965</url>
  </required_header>
  <id_info>
    <org_study_id>PEP005-001</org_study_id>
    <secondary_id>2005/145</secondary_id>
    <nct_id>NCT00107965</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 &amp; 2 or Day 1 &amp; 8 Applications to Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peplin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peplin</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether topical application of PEP005 is safe for
      the treatment of actinic keratoses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of PEP005 Topical Gel at 0.0025%, 0.01%, and 0.05% administered as two applications to patients with actinic keratosis (AKs) on the arms, shoulders, chest, face, and/or scalp</measure>
    <time_frame>85 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of PEP005 0.0025%, 0.01% and 0.05% Topical Gel in treating Actinic Keratoses</measure>
    <time_frame>85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment>60</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>0.0025% PEP005 Topical Gel (Day 1,2 application)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>0.01% PEP005 Topical Gel (Day 1,2 application)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>0.05% PEP005 Topical Gel (Day 1,2 application)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>Vehicle Gel (Day 1,2 application)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>0.0025% PEP005 Topical Gel (Day 1,8 application)</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>0.01% PEP005 Topical Gel (Day 1,8 application)</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>0.05% PEP005 Topical Gel (Day 1,8 application)</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005</intervention_name>
    <description>Vehicle Gel (Day 1,8 application)</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients

          -  At least five individual AK lesions on the arms, shoulders, chest, face and/or scalp

        Exclusion Criteria:

          -  A cosmetic or therapeutic procedure:

               -  within 10 cm of the selected AK lesions during the 3 months prior to study entry
                  or

               -  anywhere during the 4 weeks prior to study entry or anticipated treatment during
                  the study

          -  Treatment with 5-fluorouracil, imiquimod, diclofenac or photodynamic therapy:

               -  of lesions located within 10 cm of the selected AK lesions during the 3 months
                  prior to study entry or

               -  anywhere during the 4 weeks prior to study entry or anticipated treatment during
                  the study

          -  Use of acid-containing products, topical retinoids or light chemical peels within 10
             cm of the selected AK lesions during the 3 months prior to study entry, or anticipated
             treatment in this same area during the study

          -  Treatment with immuno-modulators, cytotoxic drugs, or interferon/interferon inducers
             during the 4 weeks prior to study entry or anticipated treatment during the study

          -  Treatment with psoralen plus UVA or use of UVB therapy during the 6 months prior to
             study entry or anticipated treatment during the study

          -  Use of systemic retinoids during the 6 months prior to study entry or anticipated
             treatment during the study

          -  Anticipated excessive or prolonged exposure to ultraviolet light or use of topical
             salves, creams or ointments to the selected AK lesions during the study

          -  Females of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Siller</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siller Medical</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Foundation</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Dermaology Clinic</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2005</study_first_submitted>
  <study_first_submitted_qc>April 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2005</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <name_title>Janelle Katsamas</name_title>
    <organization>Peplin</organization>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Solar Keratosis</keyword>
  <keyword>AK</keyword>
  <keyword>Sun spots</keyword>
  <keyword>PEP005</keyword>
  <keyword>Topical</keyword>
  <keyword>Dermatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

